Insights
- Syensqo and Emulseo have declared their intention to work together to further the development of microfluidic technology, specifically for use in medical settings.
- The goal of this collaboration is to create cutting-edge methods for medication delivery, diagnostics, and personalised medicine.
- The partnership is expected to increase the use of microfluidic technologies in industrial and medical settings.
The French business Emulseo, which specialises in formulations for microfluidic technology—the manipulation of liquids at the tiny scale—has partnered with Syensqo, a prominent speciality chemicals company. In accordance with this agreement, Emulseo will incorporate Syensqo’s cutting-edge solution, Galden PFPE, into its Fluo-Oil product line to give its clients a crucial part of developing dependable and effective droplet-based microfluidic investigations.
A popular method for studying and modifying liquids at the microscale with liquid micro-droplets is droplet-based microfluidics analysis. Because it is one of the most accurate and effective methods for studying DNA strands, cells, chemicals, or medications using extremely little quantities of material, it has a wide range of uses, especially in the medical field. For instance, it is employed in the quick COVID-19 testing using digital PCR, the creation of antibiotics and medicinal therapies, and the detection of malignant disorders from blood samples.
The collaboration with Emulseo will make use of Syensqo’s Galden PFPE, a series of high-performance, fluorinated fluids that are inert and have exceptional qualities that allow microfluidic devices to operate at their best. These qualities primarily include their optical clarity, low viscosity, and chemical inertness. “We are excited to collaborate with Emulseo and advance our Galden PFPE to the cutting edge of microfluidics technology,” stated Peter Browning, who leads Syensqo’s Speciality Polymers Global business segment. “This partnership highlights our dedication to innovation and broadening the uses of our materials to benefit mankind, as our PFPE, which is typically utilised in the electronics sector, will now help save lives by, for instance, accelerating the development of vaccines and detecting cancer.”
Emulseo CEO Florine Maes continued, “As a young, creative company, Emulseo is extremely proud to partner with a European industry leader such as Syensqo with a clear ambition to support innovation and to contribute to the development of cutting edge technologies in the health sector.””Our product offerings will be enhanced to meet our commitments to our scientific and industrial customers worldwide, thanks to Synsqo’s high performance chemicals, our expertise, and custom quality controls for microfluidic requirements.”